1. US Food and Drug Administration (FDA) (2014) Guidance for Industry. Immunogenicity assessment for therapeutic protein products. Published as a notice in the Federal Register: 79 Fed. Reg. 47649, August 14, 2014. Docket No. FDA-2013-D-0092.
2. Committe for Medicinal Product for Human Use (CHMP) ( draft) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (draft guidance). Doc. Ref. EMEA/CHMP/BMWP/14327/2006, London, 2016.
3. US Food and Drug Administration (FDA) (2016) Guidance for industry: assay development forimmunogenicity testing of therapeutic proteins (draft guidance). Published as a notice in the Federal Register: 81 FR 24106, April 2016. Docket No. FDA-2009-D-0539.
4. Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals: J Int Assoc Biol Stand. 2011;39(2):100–9.
5. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1–2):1–9.